Poster 4



First Case report of Aspergillosis in COVID-19 patients at Medina, Saudi Arabia

Aiah M Khateb¹, Fadwa S. Alofi ², Ziab Zakey³ Alahmadey, Abdullah Almutairi⁴

²Department of Medical Laboratory Technology, Collage of Applied Medical Science, Taibah University, Madina, Saudi Arabia, ²Infectious Diseases Department, King Fahad Hospital, Almadinah Almunawwarah, Saudi Arabia, ³Clinical Laboratory Department, Ohud hospital, Ministry of Health, Medina, Saudi Arabia, ⁴Microbiology laboratory, King Fahad Hospital, Almadinah Almunawwarah, Saudi Arabia


Abstract

Background: Since the beginning of Coronavirus diseases 2019 (COVID-19) it has been associated with an invasive fungal infection. Several COVID19 cases were complicated due to co-infection with *Aspergillus, Rhizopus, Mucor* and other mould species. This complication usually results in deteriorating patient prognosis, prolonging hospital stay and possible mortality. The study aims is to present a case with COVID-19 pulmonary Aspergillosis fungal infection.

Material and methods referred COVID cases from Ohud hospital for microbiology diagnosis at King Fahad Hospital in Medina (KFH) Data was collected from health records, clinical and radiological report, and laboratory test including respiratory culture of sputum and bronchial wash, blood culture, complete blood count (CBC).

Results: A 72-year-old male patient presented with fever, cough, severe shortness of breath and abdominal pain that persisted for a week. The patient was admitted to the hospital on the 7th of April 2020, on the same day he was intubated and admitted to ICU. The patient was diabetic and hypertensive and COVID19 pneumonia was confirmed. Soon after, the patient became septic, and his blood culture grow *Candida albican*. His sputum culture was positive for *Acinetobacter* spp. The patient was treated with a broad range of antibiotics and antifungal which included, colistin, tigecycline, vancomycin, meropenem and caspofungin. The patient's hospital course was complicated with hospital acquired pneumonia. His sputum culture was positive for *Aspergillus ustus*. Immediately, the patient case was complicated with septic shock, acute kidney injury and disseminated intravascular coagulation (DIC). Sadly, the patient died on 13 May 2020

Conclusion: Invasive fungal infections are characterizedzed with high mortality. Early diagnosis is key and screening for resistance is curial for successful treatment. There is a great need for reporting such fungal infections to provide appropriate diagnostic tools that are lacking



Laboratory diagnosis




Fig 2. Respiratory culture results for sputum sample was Aspergillus ustus. A-C)Macroscopic examination: colony starts brownish yellow to purple grey becoming grey to charcoal. Reverse is reddish yellow. D-E) Microscopic examination: short rough stalks coloured pale yellow, arising from foot cells, round vesical with mutuale and and phialides covering two thirds, no hulle cells seen. Conidia were rough round 3.5µm size.

Discussions

- It is challenging to diagnose COVID-19-associated invasive pulmonary aspergillosis (CAPA). In Aspergillus genus, most isolated causative agents were Aspergillus fumigatus and Aspergillusi niger.
- Aspergillus ustus rarely causes cutaneous infections. It
 has been reported to cause onychomycosis and otitis
 media. However, it can be nosocomially acquired in
 severely immunosuppressed patients. In this risk
 group mortality rate is 50%. and short survival
- Previous literature reported high MIC of Aspergillus ustus towards Caspofungin and triazoles. Leading to less effective treatment
- This patient's case was complicated with multiple comorbidities in addition respiratory disease and fungemia.

References

- 1-Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Journal of Fungi. 2021 Nov;7(11):921.
- 2-Verweij, PF., yan den Bergh, MF., Rath, PM; de Pauw, BE; Voss, A; Meis, JF. (May 1999). Journal of Clinical Microbiology. 37 (5): 1606–9. doi:10.1128/jcm.37.5.1606–
- 3-Panackal, Anil A.; Imhof, Alexander, Hanley, Edward W.; Marr, Kieren A. (2006). Emerging Infectious Diseases. 12 (3): 403—8. doi:10.3201/eld1203.050670. PMC 3291430. PMID 16704776.
- 4-Azzola, A., J. R. Passweg, J. M. Habicht, L. Bubendorf, M. Tamm, A. Gratwohl, and G. Eich. 2004. J. Clin. Microbiol. 42:4805-4808.
- 5-Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. Antimicrobial Agents and Chemotherapy. 2001 Jan 1;45(1):327-30.